• Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

    3 days ago - By News Medical

    A new analysis of B cells and more than 1,000 different monoclonal antibodies from 8 patients with COVID-19 shows that, contrary to previous hypotheses, protective B cell responses to the SARS-CoV-2 spike protein remain stable and continue to evolve over a 5-month period, many months after the initial period of active viral replication.
    Read more ...

     

  • Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

    4 days ago - By News Medical

    A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies directed against the coronavirus that causes Middle East respiratory syndrome found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
    Read more ...